Business Wire

Lumen Health Tech Company Reveals New Data About Metabolism Training

Share

Lumen, a health technology company at the forefront of metabolic health, has uncovered new data that reveals how training your metabolism is the greatest contributor to sustainable health and weight loss, not crash dieting.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210107005400/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Lumen metabolism insights (Photo: Lumen)

The data analysis is based on 1 million metabolism measurements throughout 2020, as Lumen data scientists have discovered that metabolic flexibility, or the body's ability to efficiently switch between carbs and fats as an energy source, is the key to optimal health.

By focusing on optimising their metabolism, users were able to increase metabolic flexibility by 33%. Two-thirds also reported losing weight at a rate of 2 pounds per week on a consistent basis.

On the nutrition end, users successfully completed an average of 12 hour fasts and mostly followed their personalised nutrition plan according to what their metabolism measurement prescribed. The top 2% were able to start their day in a state of burning fat for 4 consecutive days. Naturally, users also became more active and completed an average of 1000 more steps a day, and slept at least 7 hours.

That's equivalent to walking to the supermarket, doing one weekly workout at home, eating a couple carb servings per meal with room for low-carb snacks, and eating dinner by 7pm followed by a decent night of sleep.

Research (Calcada et al, Gormsen et al) finds that people with good metabolic flexibility:

  • Are in a better position to gain muscle and perform better during workouts
  • Find it easier to lose weight and maintain it; and
  • Are at lower risk of developing obesity, diabetes and metabolic disorders.

"Understanding how your body reacts to what you eat and how you exercise is crucial to training your metabolism. The base of performance, health and weight loss starts with your metabolism- and we are able to see the data of users worldwide improving their health every day just by being more aware of their body," said Barak Alon, head of data at Lumen.

In an effort to raise awareness for metabolic health and its many benefits, Lumen is launching a campaign entitled "New year, new metabolism" through a resource center with a downloadable health kit including extensive insights on nutrition and exercise to optimise metabolic health and flexibility.

About Lumen

Lumen is a device and app that measures your metabolism in a single breath through a complex algorithm and provides daily personalised nutrition based on your metabolic data. At Lumen, we believe that a healthy metabolism is the key to better health, and that everyone can attain it with a little help from Lumen.

Founded in 2014 by scientists and experienced entrepreneurs, Lumen is the biggest metabolic measurement platform in the world, with over 1,000,000 measurements per month.

Our technology provides individuals with new metrics on metabolism and a system to keep them accountable so they can achieve their health and wellness goals and prevent long-term chronic illness by improving their metabolic health.

Scientific Validation

Lumen can provide numerous insights about the metabolism of an individual, as well as valuable scientific data to increase knowledge of metabolic flexibility and nutrition. In a study conducted by San Francisco State University, Lumen has been validated to meet the gold standard for metabolic measurement.

Availability

The Lumen device is available at Lumen.me, currently priced at £299 with an MSRP of £349. The device comes equipped with a travel case, charging dock, USB-C Cable, and Premium Customer Support. Users can download the app for free on the Apple App Store and on Google Play.

Follow us on twitter.com/LumenMetabolism, facebook.com/Lumen.me/, instagram.com/lumen.me/, youtube.com/c/Lumendotme

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media contact: Kyla Blumenfeld, press@lumen.me
+972548161939

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye